Market Closed -
Other stock markets
|
After market 03:59:45 pm | |||
184.4 EUR | +2.84% | 185.2 | +0.41% |
Jun. 03 | SARTORIUS STEDIM BIOTECH : EPS cut (2023: -13.7%, 2024: -16.4%) | |
May. 16 | Sartorius sinks again towards year low | DP |
Sales 2024 * | 2.94B 3.19B | Sales 2025 * | 3.33B 3.62B | Capitalization | 17.45B 18.96B |
---|---|---|---|---|---|
Net income 2024 * | 335M 364M | Net income 2025 * | 451M 490M | EV / Sales 2024 * | 6.72 x |
Net Debt 2024 * | 2.27B 2.47B | Net Debt 2025 * | 2.16B 2.35B | EV / Sales 2025 * | 5.89 x |
P/E ratio 2024 * |
50.5
x | P/E ratio 2025 * |
36.3
x | Employees | 10,493 |
Yield 2024 * |
0.41% | Yield 2025 * |
0.61% | Free-Float | 31.97% |
Latest transcript on Sartorius Stedim Biotech
1 day | +2.84% | ||
Current month | +0.96% | ||
1 month | -10.49% | ||
3 months | -26.74% | ||
6 months | -6.30% | ||
Current year | -23.01% |
Managers | Title | Age | Since |
---|---|---|---|
René Fáber
CEO | Chief Executive Officer | 48 | 19-03-25 |
Chairman | 59 | 07-06-28 | |
Chief Tech/Sci/R&D Officer | 59 | 09-04-28 |
Members of the board | Title | Age | Since |
---|---|---|---|
Henri Riey
BRD | Director/Board Member | 62 | 07-06-28 |
Chairman | 59 | 07-06-28 | |
Susan Dexter
BRD | Director/Board Member | 67 | 15-04-06 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.42% | 17 M€ | +7.25% | - | |
0.35% | 5 M€ | +4.56% |
Date | Price | Change | Volume |
---|---|---|---|
24-06-05 | 184.4 | +2.84% | 56 218 |
24-06-04 | 179.3 | -1.24% | 57,959 |
24-06-03 | 181.6 | -0.60% | 62,448 |
24-05-31 | 182.6 | -0.27% | 167,808 |
24-05-30 | 183.2 | -0.68% | 53,302 |
Real-time Euronext Paris, June 05, 2024 at 11:38 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-23.01% | 18.99B | |
-6.65% | 180B | |
-0.73% | 109B | |
-3.28% | 68.93B | |
-4.07% | 46.41B | |
+12.73% | 45.43B | |
+7.38% | 43.26B | |
+19.21% | 30.05B | |
+16.10% | 25.19B | |
-7.38% | 23.34B |
- Stock Market
- Equities
- DIM Stock